Advertisment
Bayer to unveil new phase III research on menopause symptom treatment at ESG 2025
Bayer will present additional research results from its Phase III development program with elinzanetant on treating menopause symptoms at the upcoming 16th Congress of the European Society of Gynecology (ESG) which takes place from March 19 – 22 in Riga, Latvia. Results include the impact of sleep disturbances on women’s health and quality of life as well as the effect of elinzanetant for the treatment of vasomotor symptoms associated with menopause and pooled data from several subgroup analyses from two Phase III studies with elinzanetant.
The research to be presented demonstrates the continuous commitment of Bayer as a leader in women’s healthcare to advance science, increase awareness and education around menopause as well as to broaden therapeutic options in an area of high unmet medical need.
Bayer oral presentation at ESG 2025 of interest:
- Oral presentation: “Associations between Vasomotor Symptoms, Sleep Disturbances, and Frequent Mood Changes in Menopausal Women: Analysis of Data from the Study of Women’s Health Across the Nation”
o Carina Dinkel-Keuthage
- Friday, March 21st,2025: 09:45-11:15 EET, Hall GAMMA
Bayer additional presentations at ESG 2025 include:
- Poster #52: “Sleep disturbance in menopausal women with vasomotor symptoms: findings from two Phase 3 studies”
o Cecilia Caetano
o Wednesday, March 19th, 2025, 18:30-20:00 EET, Foyer 2
- Poster #53: “Effect of elinzanetant for the treatment of vasomotor symptoms associated with menopause: pooled data from two Phase 3 studies”
o Nick Panay
o Wednesday, March 19th, 2025, 18:30-20:00 EET, Foyer 2
- Poster #55: “EMPOWER: Evaluating Menopausal symPtom treatment Options and WomEns’ pReferences”
o Cecilia Caetano
o Wednesday, March 19th, 2025, 18:30-20:00 EET, Foyer 2
- Poster #58: “Does sleep disturbance have an impact on depression and anxiety in perimenopausal and postmenopausal women? A Europe-based survey“
o Carina Dinkel-Keuthage
o Wednesday, March 19th, 2025, 18:30-20:00 EET, Foyer 2
- Poster #61: “Effect of elinzanetant for the treatment of vasomotor symptoms associated with menopause across BMI and smoking history subgroups: pooled data from two Phase 3 studies”
o Rosella E Nappi
o Wednesday, March 19th, 2025, 18:30-20:00 EET, Foyer 2
- Poster #62: “Effect of elinzanetant for the treatment of vasomotor symptoms associated with menopause across race and ethnicity subgroups: pooled data from two Phase 3 studies”
o Rosella E Nappi
o Wednesday, March 19th, 2025, 18:30-20:00 EET, Foyer 2
Elinzanetant is the first dual neurokinin-1 and 3 (NK-1,3) receptor antagonist, in late-stage clinical development for the targeted treatment of moderate to severe VMS associated with menopause or caused by adjuvant endocrine therapy for breast cancer, administered orally once daily. Data from OASIS 1 and 2 were published in the Journal of the American Medical Association (JAMA)3 in August 2024. Detailed results of the Phase III study OASIS 3 providing additional efficacy and safety data over 52 weeks were presented at The Menopause Society (TMS) annual meeting in September 2024. Based on the positive results from the Phase III clinical development program, submissions for marketing authorizations for elinzanetant are ongoing in the US, EU and other markets around the world. In early 2025, positive topline results of OASIS 4 the first pivotal international Phase III study to assess the safety and efficacy of elinzanetant in moderate to severe VMS caused by adjuvant endocrine therapy were announced with details planned to be presented at upcoming scientific congresses.
